Skip to main content
. Author manuscript; available in PMC: 2023 Sep 13.
Published in final edited form as: Alzheimers Dement. 2022 Sep 24;19(4):1403–1414. doi: 10.1002/alz.12787

Figure 1. Associations between creatinine, body mass index, comorbidities and medication use with plasma biomarkers.

Figure 1.

Standardized beta coefficients and 95% confidence interval from linear regression models adjusted for age and sex with plasma biomarkers in BioFINDER-1 (left) and BioFINDER-2 (right). The Aβ42/40 ratio was reversed so that the effect size moves in the same direction for each biomarker. As such, higher value on each biomarker is more abnormal (towards AD). Stars indicate that the association remained significant when further adjusting for flutemetamol global Aβ-PET SUVR. In BioFINDER-2, all associations also remained significant if adding temporal meta-ROI tau-PET SUVR from [18F]RO948 as a covariate.

Abbreviations: Aβ, beta-amyloid; BMI, body mass index; CSF, cerebrospinal fluid, GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p-tau217, phosphorylated tau 217